4CPS-128 Effectiveness of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer

BACKGROUND: Abiraterone acetate (AA) and enzalutamide are authorised oral therapies in the treatment of metastatic castration-resistant prostate cancer (mCRPC), which act by inhibiting androgen synthesis. PURPOSE: To compare the effectiveness of AA and enzalutamide in patients with mCRPC. MATERIAL A...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Eur J Hosp Pharm
Autores principales: García, AM Sánchez, Mateos, A Andújar, Esquerdo, M Llinares, Irigaray, L Soriano, Torres, R Antón, Ruiz, A Navarro
Formato: Artigo
Lenguaje:Inglês
Publicado: BMJ Group 2018
Materias:
Section 4: Clinical pharmacy services
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535815/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.219
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares